48 results about "Hepatitis b core" patented technology

Genetically modified HBc polypeptides are provided.

The invention relates to a pharmaceutical composition for treating hepatitis B. The pharmaceutical composition comprises a hepatitis B surface antigen or a fragment thereof, a hepatitis B core antigenor a fragment of the hepatitis B core antigen, oligodeoxynucleotide and polysorbate 80. The pharmaceutical composition does not contain sugar, has simple components, does not have adverse reactions caused by an aluminum adjuvant, has good antigen stability, shows good preservation effect in a long-term stability experiment, can meet production, storage and use requirements of vaccines, and is suitable for large-scale production and use of therapeutic hepatitis B vaccines.

The invention discloses nanoparticles with an AIAE (aggregation-induced absorption enhancement) phenomenon as well as synthesis and an application of the nanoparticles and relates to nanoparticles. The nanoparticles with the AIAE phenomenon comprise inner cores and outer layers, wherein the inner cores are croconaine analogues, the outer layers are protein particles, the inner cores are loaded ininner cavities of the outer layers, and composite nanostructures with the croconaine analogues as the inner cores and the protein particles as the outer layers are formed. Hepatitis B core protein particles are diluted and added to a depolymerization buffer solution to be stirred; dye is uniformly stirred in DMSO, and croconaine analogue dye is obtained; the croconaine analogue dye is added to anobtained mixture and stirred, and a mixed liquid is obtained; the mixed liquid is added to a dialysis bag, dialysis is performed in an assembling buffer solution 1, and a magnetic stirring reaction isperformed; the mixed liquid is added to the dialysis bag, dialysis is performed in an assembling buffer solution 2, and a magnetic stirring reaction is performed to obtain medicine-carrying protein nanoparticles; the obtained medicine-carrying protein nanoparticles are subjected to <125>I labeling, and the nanoparticles with the AIAE phenomenon are obtained.

A gene engineering vaccine for preventing pig cysticercosis and its preparation process are disclosed. The process includes the steps: making the hepatitis B virus core protein as carrier, inserting cysticercus cellulosae protective antigen gene in multiple locations between the first amino acid to No. 183 amino acid hepatitis B core protein, cloning to procaryon expression plasmid or eucaryon expression plasmid, transforming host bacteria, expressing by inducing aim gene and acquiring aim protein or column purified eucaryon expression plasmid DNA therefore, subunit protein vaccine or nucleic acid vaccine for preventing pig cysticercosis are obtained.

The invention relates to one or more types of recombinant fusion proteins formed by hepatitis B core proteins and mycobacterium tuberculosis antigens or antigen fragments. The tuberculosis antigens or antigen fragments are inserted in the same or different permission sites of hepatitis B core proteins in a mode of single antigen or antigen fragment or various types of antigens or antigen fragments which are combined together. The recombinant fusion proteins may comprise a plurality of cofactors. In addition, the invention also relates to the type of the fusion of the tuberculosis antigen or antigen fragments and cofactors and hepatitis B core proteins, nucleic acid and amino acid sequences of coded corresponding recombinant fusion proteins, a method for preparing the recombinant fusion proteins and application of the recombinant fusion proteins in the preparation of medicaments and vaccines for preventing and / or treating tuberculosis.